MRI引导下前列腺癌优势病灶局部加量VMAT放疗的II期试验结果
一项前瞻性II期试验纳入30例mpMRI可见优势前列腺内病灶的局限性前列腺癌患者,采用VMAT同步局部加量至DIL。
要点
- mpMRI引导的DIL局部加量VMAT方案取得了极佳的形态学和生化控制。
- 治疗后6-9个月mpMRI评估DIL完全消失可作为影像学完全缓解的标志。
- 急性及晚期毒性轻微,无≥2级晚期毒性,生活质量短暂轻微下降后恢复。
关键影像表现/征象
- 治疗后6个月mpMRI显示25例完全缓解,余5例在9个月mpMRI上T2和DWI均完全消失。
- 急性泌尿毒性2级占20%(6/30),无3级急性并发症;急性直肠毒性仅2例(6.6%)均为1级。
- 晚期仅见1级泌尿和直肠并发症各3/30例,无≥2级晚期毒性。
- EPIC问卷显示泌尿、肠道和性困扰评分在治疗后前3个月轻微且不显著升高,之后恢复正常。
诊断标准与关键数值
- 生化失败采用PSA nadir+2 ng/mL标准。
- 局部控制采用mpMRI评估(6-9个月),完全缓解定义为DIL在T2和DWI上完全消失。
- 毒性分级采用CTCAE v4.0和RTOG/EORTC量表;生活质量采用IPSS、EPIC简表和UCLA-PCI问卷。
- 前列腺中位剂量77.6 Gy(IQR 77.3-78.1),DIL中位剂量85.5 Gy(IQR 85.0-86.0)。
- 中位随访30.0个月(IQR 25.5-40.27),全部患者无生化复发。
临床应用与阅片要点
- 对于mpMRI可见DIL的前列腺癌患者,可考虑MRI引导的局部加量VMAT放疗。
- 放疗后6-9个月应行mpMRI评估DIL的T2和DWI变化以判断完全缓解。
- 需关注急性泌尿毒性(20% 2级),但严重晚期毒性罕见。
局限性
- 单中心、小样本(30例)II期试验,随访时间有限(中位30个月)。
- 缺乏对照组,无法直接比较局部加量与传统放疗的优劣。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine morphological and biological control as well as toxicity and quality of life (QoL) of men with localized prostate cancer (PCa) treated with MRI-guided focal boost radiotherapy.
MATERIAL AND METHODS: 30 patients with PCa and a visible dominant intraprostatic lesion (DIL) identified on mpMRI were included in a prospective Phase II trial. Matching point registration of planning CT and T2W, diffusion-weighted and a gradient-recalled echo (GRE) MRI images made in treatment position was used for prostate and tumour delineation. Treatment consisted on 35 daily fractions of 2.17 Gy with a concomitant focal boost to the DIL of 2.43 Gy using volumetric modulated arc therapy (VMAT) and image-guided radiation therapy (IGRT) with intraprostatic fiducial markers. Biochemical failure was analysed using PSA nadir +2 ng/mL criteria and local control using mpMRI evaluation at 6-9 months following RT. Acute and late toxicity were defined according to CTCAE v.4.0 and RTOG/EORTC scales and QoL was assessed using IPSS, EPIC short-form and UCLA-PCI questionnaires.
RESULTS: The median radiation dose to the prostate was 77.6 Gy (IQR 77.3-78.1), and to the DIL was 85.5 Gy (IQR 85.0-86.0). With a median follow up of 30.0 months (IQR 25.5-40.27), all patients remain free of biochemical relapse. An mpMRI complete response was observed in 25 patients during the first post-treatment evaluation at 6 months. The remaining five patients achieved a complete disappearance of the DIL both on T2 and DWI on the second mpMRI performed at 9 months following treatment. Six out of 30 (20%) patients presented acute Grade 2 urinary toxicity with no Grade 3 acute complications. Acute rectal toxicity was only found in 2 (6.6%) patients (both Grade 1). Only late Grade 1 urinary and rectal complications were observed in 3/30 patients, respectively, with no Grade 2 or more late toxicity. The urinary, bowel and sexual bother EPIC scores were slightly and insignificantly increased in the first 3 months post-treatment, returning to normal afterwards.
CONCLUSIONS: mpMRI-guided focal boost using VMAT hypofractionated technique is associated with an excellent morphological and functional response control and a safe toxicity profile.
ADVANCES IN KNOWLEDGE: In the present trial, we examined the potential role of mpMRI for radiological assessment (functional and morphological) of treatment response in high-risk prostate cancer patients treated with MRI-guided focal radiotherapy dose intensification to dominant Intraprostatic lesion.
引用
- Zapatero A, Roch M, Castro Tejero P, et al. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial. Br J Radiol. 2021. PMID: 34538073. doi:10.1259/bjr.20210683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。